Get the Stockscreener App
19.37
0.57%
0.11
After Hours:
19.37
Mediwound Ltd stock is traded at $19.37, with a volume of 46,749.
It is up +0.57% in the last 24 hours and down -11.79% over the past month.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
See More
Previous Close:
$19.26
Open:
$19.22
24h Volume:
46,749
Relative Volume:
0.64
Market Cap:
$230.10M
Revenue:
$19.85M
Net Income/Loss:
$-12.75M
P/E Ratio:
-14.04
EPS:
-1.38
Net Cash Flow:
$-21.94M
1W Performance:
+2.00%
1M Performance:
-11.79%
6M Performance:
+8.15%
1Y Performance:
+24.81%
1-Day Range:
$19.12
$19.69
1-Week Range:
$19.11
$19.87
52-Week Range:
$14.14
$24.00
Mediwound Ltd Stock (MDWD) Company Profile
Compare MDWD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDWD
Mediwound Ltd
|
19.37 | 230.10M | 19.85M | -12.75M | -21.94M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Mediwound Ltd Stock (MDWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-02-25 | Initiated | Alliance Global Partners | Buy |
| Feb-28-25 | Initiated | Craig Hallum | Buy |
| Jul-16-24 | Reiterated | Maxim Group | Buy |
| Dec-22-22 | Initiated | Maxim Group | Buy |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Sep-23-20 | Initiated | BTIG Research | Buy |
| Nov-28-16 | Initiated | Aegis Capital | Buy |
| Aug-17-16 | Initiated | Wells Fargo | Outperform |
| Apr-16-14 | Initiated | Oppenheimer | Outperform |
View All
Mediwound Ltd Stock (MDWD) Latest News
Bank of America Corp DE Has $141,000 Holdings in MediWound Ltd. (NASDAQ:MDWD) - Defense World
(MDWD) On The My Stocks Page - news.stocktradersdaily.com
Analysts Set MediWound Ltd. (NASDAQ:MDWD) PT at $31.25 - Defense World
When (MDWD) Moves Investors should Listen - news.stocktradersdaily.com
MediWound (NASDAQ:MDWD) Now Covered by Oppenheimer - Defense World
Oppenheimer assumes MediWound stock at outperform, sets $34 PT By Investing.com - Investing.com India
Oppenheimer assumes MediWound stock at outperform, sets $34 PT - Investing.com
Oppenheimer Adjusts MediWound Price Target to $34 From $36, Maintains Outperform Rating - marketscreener.com
MediWound (MDWD) Garners Outperform Rating with Strategic Advanc - GuruFocus
Companies Like MediWound (NASDAQ:MDWD) Are In A Position To Invest In Growth - Yahoo Finance
What is HC Wainwright’s Forecast for MediWound Q2 Earnings? - Defense World
Northern Trust Corp Has $2.58 Million Holdings in MediWound Ltd. (NASDAQ:MDWD) - Defense World
MediWound (NASDAQ:MDWD) PT Set at $31.00 by HC Wainwright - Defense World
Where are the Opportunities in (MDWD) - news.stocktradersdaily.com
H.C. Wainwright lifts MediWound stock target to $31, maintains buy By Investing.com - Investing.com South Africa
H.C. Wainwright lifts MediWound stock target to $31, maintains buy - Investing.com
MDWD: HC Wainwright & Co. Raises Price Target for MediWound | MD - GuruFocus
MediWound (MDWD) Target Price Raised by Analyst | MDWD Stock News - GuruFocus
MediWound (MDWD) Target Price Raised by Analyst | MDWD Stock New - GuruFocus
MediWound Ltd (MDWD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline - Yahoo Finance
MediWound’s Q1 2025: Strategic Progress Amid Financial Challenges - TipRanks
Mediwound earnings beat by $0.58, revenue fell short of estimates - Investing.com India
MediWound (MDWD) Q1 2025 Earnings Call Transcript - Mitrade
MediWound: Q1 Earnings Snapshot - MySA
MediWound Q1 2025 Earnings Call Transcript - MarketBeat
Transcript : MediWound Ltd., Q1 2025 Earnings Call, May 21, 2025 - marketscreener.com
MediWound Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
MediWound Ltd. Reaffirms Revenue Guidance for the Year 2025 - marketscreener.com
MediWound (MDWD) Projects Revenue Growth for Fiscal Year 2025 | - GuruFocus
MediWound Announces Q1 2025 Results and Updates on Key Trials - TipRanks
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
MediWound (MDWD): Q1 Revenue Falls Short, Strategic Growth Plans Intact | MDWD Stock News - GuruFocus
MediWound Expands Global Reach: Major Wound Care Players Join Clinical Trials as Revenue Targets $24M - Stock Titan
Earnings To Watch: MediWound Ltd (MDWD) Reports Q1 2025 Result - GuruFocus
MediWound Stock: Undervalued High-Growth Potential (NASDAQ:MDWD) - Seeking Alpha
MediWound Announces Key Approvals at 2025 Shareholder Meeting - TipRanks
We Think MediWound (NASDAQ:MDWD) Can Afford To Drive Business Growth - simplywall.st
MediWound (MDWD) to Release Earnings on Wednesday - Defense World
MediWound (MDWD) Showcases Phase II Trial Results in Wound Care - GuruFocus
EscharEx shows promise in venous ulcer treatment - Investing.com Australia
MediWound Announces Publication of Phase II EscharEx® Data Demon - GuruFocus
MediWound Announces Publication of Phase II EscharEx® Data - GlobeNewswire
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers - Stock Titan
Barclays PLC Raises Stock Position in MediWound Ltd. (NASDAQ:MDWD) - Defense World
MediWound Ltd. (NASDAQ:MDWD) Shares Sold by Renaissance Technologies LLC - Defense World
Mediwound Ltd Stock (MDWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):